Maria manages her mother’s medications. There are seven of them. She picks them up on the last Friday of every month at a Walgreens in San Antonio, running the errand after work, before her mother’s dinner. She knows the prices the way you know gas prices when you drive a lot — not precisely, but in the range of what they should be, and immediately when something changes.
Last month something changed.
President Trump signed an executive order this week imposing 100 percent tariffs on imported pharmaceuticals. The stated goal is to bring drug manufacturing back to the United States — to end what the administration describes as a dangerous dependency on foreign supply chains for medicines that Americans need every day.
The structural argument has genuine merit. The United States does depend heavily on foreign manufacturing for the active pharmaceutical ingredients that go into most branded and generic drugs. China and India together supply the majority of those ingredients. The concentration is real. The vulnerability is real. The question of whether a 100 percent tariff is the mechanism that addresses it — or whether it primarily addresses the household budget of someone like Maria — is a different question, and one the order does not answer.
The pharmaceutical supply chain is not a simple thing. A drug that is packaged in New Jersey may contain an active ingredient synthesized in Hyderabad from a precursor chemical manufactured in Wuhan. The finished pill is domestically packaged. The content is not. Tariff schedules applied to finished drugs and to active pharmaceutical ingredients have different effects on different parts of the chain, and the order’s specific scope — which categories, which compounds, which stages of manufacturing — determines who bears the cost and by how much.
What is reliably true of tariffs on essential goods is where the cost lands. Manufacturers facing new input costs have a limited set of options: absorb the cost in margin, pass it through to buyers, or find alternative suppliers. In the pharmaceutical industry, the first option is constrained by the fact that generic drug margins are already thin — the entire generic market is built on cost competition. The second option is what happens next. Alternative sourcing takes years to build; factories cannot be reshored in a quarter. So in the short and medium term, the cost moves downstream.
Downstream is the pharmacy counter. Downstream is Maria on the last Friday of the month.
The drugs most likely to see near-term price exposure are generics. Brand-name drugs are manufactured under more varied and often more domestic arrangements. Generics — the drugs that make the difference between a manageable monthly budget and an impossible one for the majority of Americans managing chronic conditions — are the drugs most dependent on imported active ingredients.
The most commonly prescribed drug in the United States is a generic statin. The second is a generic for blood pressure. The third, fourth, and fifth are generics for diabetes, thyroid conditions, and anxiety. These are not specialty drugs. They are the maintenance medications that tens of millions of Americans take every day, fill every month, and pay for — partially, after insurance, with the copay and the deductible — out of pocket.
A 100 percent tariff does not double the price of a drug at the pharmacy counter. The relationship between input costs and retail prices runs through manufacturers, wholesalers, pharmacy benefit managers, insurers, and retail pharmacy pricing structures — each of which has its own margin, its own contract, its own pricing logic. What it does is introduce an upstream cost that works its way through that chain over time, arriving at the counter in the form of a price that was $18 last month and is $27 this month, or a formulary change that means the preferred drug is now the tier-three drug, or a coverage decision that shifts more cost onto the patient.
Maria will not receive a letter explaining why the number changed. She will just notice that it did.
The reshoring argument — that tariffs will incentivize domestic manufacturing and reduce dependency — operates on a longer timeline than the cost impact. Building a pharmaceutical manufacturing facility capable of producing active ingredients at scale takes five to ten years and hundreds of millions of dollars in capital investment. The regulatory approval process for new manufacturing sites adds additional time. The workforce required — chemists, process engineers, quality control specialists — does not exist in large enough numbers domestically to staff a rapidly expanded manufacturing base.
This does not mean reshoring is impossible or undesirable. It means the cost is paid now and the benefit, if it materializes, arrives later. The person paying the cost in the near term is not the person most likely to be employed in a domestic pharmaceutical plant in 2031.
The administration’s instinct — that American dependency on foreign supply chains for essential medicines is a national security problem — is a defensible instinct. A conflict that disrupts shipping through a strait, or a diplomatic rupture that cuts off a key supplier, could have real consequences for drug availability. The COVID pandemic demonstrated what happens when supply chains snap under pressure, and pharmaceuticals were not immune.
But the mechanism chosen to address that dependency has a specific distributional shape. It costs money immediately. It costs it most to people who have the least margin to absorb it. It offers a future benefit that is genuinely uncertain — because building domestic manufacturing capacity requires not just the tariff incentive but the capital, the regulatory environment, the workforce, and the sustained policy commitment to see it through.
Maria’s mother takes a blood pressure medication, a statin, a low-dose aspirin, a thyroid drug, a drug for acid reflux, a vitamin D supplement her doctor prescribed after a bone density test, and a generic antidepressant she has been on for eleven years. Six of the seven are generics. Five of those six depend on imported active ingredients.
The executive order was signed this week. The timeline for when it affects the bill at the pharmacy counter is not a matter of if. It is a matter of when, and by how much, and whether anyone in the supply chain absorbs enough of it that Maria doesn’t have to choose.
